Evidence map›Paper›PMID 16369008›Full record

ArticleInfection and immunity2006

A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.

Eric J Tarcha, Venkatesha Basrur, Chiung-Yu Hung, Malcolm J Gardner, Garry T Cole

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 69 citations in OpenAlex.

  1. mBio · 2024
    Article
  2. Review
  3. Review
  4. The Host Response to Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024
    Review
  5. Review
  6. Review
  7. Antibody screening reveals antigenic proteins involved inFrontiers in cellular and infection microbiology · 2023
    Article
  8. Review
  9. Characterization of the Growth and Morphology of a BSL-2Journal of fungi (Basel, Switzerland) · 2022
    Article
  10. Current Landscape of Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2022
    Review
  11. Review
  12. A Review ofCurrent clinical microbiology reports · 2021
    Review
  13. Advances in Fungal Peptide Vaccines.Journal of fungi (Basel, Switzerland) · 2020
    Review
  14. The Rise ofFrontiers in immunology · 2019
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Eric J TarchaDepartment of Biology University of Texas at San Antonio, Margaret Batts Tobin Building, Rm. 1.308E, 6900 North Loop 1604 West, San Antonio, TX 78249, USA.
Venkatesha Basrur
Chiung-Yu Hung
Malcolm J Gardner
Garry T Cole
University of Toledo Medical Center · US

Funding

Coccidiodes immitis Genome Sequencing ProjectU01AI050910 · NIAID · INSTITUTE FOR GENOMIC RESEARCH · PI GARDNER, MALCOLM JOHN · 2001 to 2002
$2.9M
IMMUNOREACTIVE MACROMOLECULES OF COCCIDIOIDES CELL TYPESR01AI019149 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI COLE, GARRY THOMAS · 1986 to 2006
$2.2M
IMMUNOREACTIVE MACROMOLECULES OF COCCIDIOIDES CELL TYPESR37AI019149 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI COLE, GARRY THOMAS · 1992 to 2001
$894k
NIAID NIH HHS AI 19149NIAID NIH HHS R01 AI019149NIAID NIH HHS R37 AI019149NIAID NIH HHS U01 AI050910NIAID NIH HHS U01 AI 50910
6 · The paper itself

Abstract

Coccidioidomycosis is a respiratory disease of humans caused by the desert soil-borne fungal pathogens Coccidioides spp. Recurrent epidemics of this mycosis in the southwestern United States have contributed significantly to escalated health care costs. Clinical and experimental studies indicate that prior symptomatic coccidioidomycosis induces immunity against subsequent infection, and activation of T cells is essential for containment of the pathogen and its clearance from host tissue. Development of a human vaccine against coccidioidomycosis has focused on recombinant T-cell-reactive antigens which elicit a durable protective immune response against pulmonary infection in mice. In this study we fractionated a protective multicomponent parasitic cell wall extract in an attempt to identify T-cell antigens. Immunoblots of electrophoretic separations of this extract identified patient seroreactive proteins which were subsequently excised from two-dimensional polyacrylamide gel electrophoresis gels, trypsin digested, and sequenced by tandem mass spectrometry. The full-length gene which encodes a dominant protein in the immunoblot was identified using established methods of bioinformatics. The gene was cloned and expressed, and the recombinant protein was shown to stimulate immune T cells in vitro. The deduced protein was predicted to contain epitopes that bind to human major histocompatibility complex class II molecules using a TEPITOPE-based algorithm. Synthetic peptides corresponding to the predicted T-cell epitopes induced gamma interferon production by immune T lymphocytes. The T-cell-reactive antigen, which is homologous to secreted fungal aspartyl proteases, protected mice against pulmonary infection with Coccidioides posadasii. We argue that this immunoproteomic/bioinformatic approach to the identification of candidate vaccines against coccidioidomycosis is both efficient and productive.

Indexed as

Amino Acid SequenceAnimalsAspartic Acid EndopeptidasesCell ExtractsCell WallCoccidioidesCoccidioidomycosisElectrophoresis, Gel, Two-DimensionalEpitopes, T-LymphocyteFungal VaccinesImmunoblottingLung Diseases, FungalMiceMolecular Sequence DataVaccines, SyntheticAspartic Acid EndopeptidasesCell ExtractsEpitopes, T-LymphocyteFungal VaccinesVaccines, Synthetic

Identifiers

PMID16369008
PMCPMC1346669
OpenAlexW2153797406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.